News & Events

Results of Operations and Financial Condition. On May 7, 2026, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the three months ended March 31, 2026. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information in this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any…

Results of Operations and Financial Condition. On March 27, 2026, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the year ended December 31, 2025. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information in this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any f…

Other Events On March 23, 2026, Intensity Therapeutics, Inc. (the “Company”) filed a prospectus supplement to increase the capacity of its existing “at-the-market” offering program (the “ATM”) to $60.0 million. While this filing increases the available capacity under the ATM, the Company is under no obligation to issue any shares (the “Shares”) pursuant to the program. The expanded facility is intended to enhance the Company’s financial flexibility, providing an efficient mechanism to access…

All figures in the Slide are unaudited and preliminary and are subject to the completion of financial closing procedures, including management’s reviews. As a result, this amount may differ materially from the amount that will be reflected in the Company’s financial statements as of and for the year ended December 31, 2025. The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…

Material Modifications to Rights of Security Holders. To the extent required by Item 3.03, the disclosure set forth in

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on June 6, 2025, Intensity Therapeutics, Inc. (the “Company”) received a letter (the “June 2025 Nasdaq Letter”) from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Rul…

Other Events On December 4, 2025, Intensity Therapeutics, Inc. (the “Company”) filed a prospectus supplement to increase the capacity of its existing “at-the-market” offering program (the “ATM”) to $30 million. While this filing increases the available capacity under the ATM, the Company is under no obligation to issue any shares (the “Shares”) pursuant to the program. The expanded facility is intended to enhance the Company’s financial flexibility, providing an efficient mechanism to access…

Results of Operations and Financial Condition. On November 6, 2025, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the three and nine months ended September 30, 2025. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information in this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated b…

Entry into a Material Definitive Agreement On October 30, 2025, Intensity Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investor (the “Offering”), 5,000,000 shares (the “Shares”) of common stock, par value $0.0001 per share, of the Company (“C…

Results of Operations and Financial Condition. On August 7, 2025, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the three and six months ended June 30, 2025. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information in this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by refere…

Other Events. On June 11, 2025, the Company issued a press release announcing the launch of the Offering, and on June 11, 2025, the Company issued a press release announcing the pricing of the Offering. Copies of the press releases are attached as Exhibits 99.1 and 99.2 hereto, respectively. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that involve estimates, assumptions, risks and uncertainties. Forward-looking statements include, but are not…

Entry into a Material Definitive Agreement . On June 11, 2025, Intensity Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) by and between ThinkEquity LLC (the “Underwriter”) relating to the issuance and sale of an aggregate of 6,675,000 shares (the “Firm Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), to the Underwriter at a price to the public of $0.30 per share (the “Offering”). Pursuant to the…

Unregistered Sales of Equity Securities. Simultaneously with the closing of the Offering, pursuant to the Underwriting Agreement, the Company agreed to issue to the Underwriter and/or its designees, the Representative’s Warrants to purchase up to 383,812 shares of Common Stock (representing 5% of the aggregate number of Shares sold in the Offering), as a portion of the underwriting compensation payable to the Underwriter in connection with the Offering. The Representative’s Warrants will be e…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 6, 2025, Intensity Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The notice has no immediat…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 19, 2025, Intensity Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market (the “Notice”) based on the information provided in the Company’s…

Results of Operations and Financial Condition. On May 13, 2025, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the three months ended March 31, 2025. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information in this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in an…

Results of Operations and Financial Condition. On March 13, 2025, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the year ended December 31, 2024. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information in this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any f…